Drug intelligence / Profile preview

EbsArgent

Development stage: Unknown
Lead developer: Thioredoxin Systems
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

EbsArgent is a first-in-class bactericidal antibiotic developed by Thioredoxin Systems for the treatment of multidrug-resistant urinary tract infections (UTIs). It employs a novel mechanism of action that involves ebselen and silver ions, targeting the bacterial thioredoxin enzyme system. The drug aims to address the urgent global health threat of antimicrobial resistance by offering a new class of antibiotics.

Targets

LTB4R (Leukotriene B4 Receptor 1)Prostamide R (Prostamide receptor)TXN (Thioredoxin-1)

Beyond the preview

Go deeper on EbsArgent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EbsArgent.

Explore the full profile